Adagene locks in $69 mln Series D
Adagene Inc, an oncology immunotherapy company, has raised $69 million in Series D financing.
Adagene Inc, an oncology immunotherapy company, has raised $69 million in Series D financing.
Copyright PEI Media
Not for publication, email or dissemination